Completion & Acceptability of Treatment Across Primary Care &

Status Completed

Clinical Trial Summary

This study investigates whether recent migrants to the United Kingdom are more likely to complete treatment for Latent Tuberculosis Infection (LTBI) if they are treated in the community (by General Practitioners/Family Doctors and pharmacists) than in a hospital TB clinic.

Clinical Trial Description

People with dormant/latent TB (LTBI) have TB bacteria in their bodies, but do not have any symptoms because the bacteria are not active. The investigators know that recent migrants with LTBI from countries where TB is very common (incidence greater than 150 per 100 000) are at risk of developing active TB (their dormant bacteria become active) after they arrive in the UK. Active TB can be both infectious and deadly. The treatment for LTBI is three-month course of antibiotics. This significantly reduces the risk of developing active TB. This treatment is currently arranged and supervised by hospital clinics, however, many migrants do not attend and numbers of people completing antibiotics is low. This leaves many at risk of developing active TB. This study investigates whether a community (primary care) based approach to the treatment of LTBI, coordinated by general practices and local pharmacists, will achieve higher rates of antibiotic completion. The London Borough of Newham, in the UK, has amongst the highest rates of active TB in Western Europe. As part of a strategy to tackle this disease burden, an innovative model of care has been implemented in the borough in which GPs and pharmacists screen and treat migrants with LTBI. Our trial will evaluate whether primary care based management of LTBI leads to higher rates of treatment completion amongst recent migrants when compared to hospital based care. This approach would save money (both for the health service and for patients in terms of travels costs) and reduce numbers of new cases of active TB. The treatment for Latent Tuberculosis Infection will be 3 months of combined oral Rifampicin and Isoniazid with Pyridoxine. The dosage is weight dependent. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03069807
Study type	Interventional
Source	Queen Mary University of London
Contact
Status	Completed
Phase	N/A
Start date	January 2017
Completion date	March 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05073926` - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Not yet recruiting	`NCT04428294` - Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation	Phase 4
Completed	`NCT02276755` - Vitamin D Supplementation in TB Prevention	Phase 3
Withdrawn	`NCT03498534` - Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis	Phase 4
Active, not recruiting	`NCT03988933` - 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.	Phase 2
Recruiting	`NCT06022146` - TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts	Phase 3
Active, not recruiting	`NCT04188041` - Improving Rhode Island's Tuberculosis Preventive Services in Primary Care	N/A
Recruiting	`NCT03730181` - Tuberculosis Clinical Trials Consortium Study 35	Phase 1/Phase 2
Completed	`NCT01967134` - Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis	Phase 1
Completed	`NCT00257907` - Immune Response to Mycobacterium Tuberculosis Infection
Recruiting	`NCT05756582` - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Active, not recruiting	`NCT04557176` - TB Screening Improves Preventive Therapy Uptake	N/A
Completed	`NCT02119130` - Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa	N/A
Not yet recruiting	`NCT06281834` - Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention	Phase 1
Not yet recruiting	`NCT02512484` - Improving the Detection of Active Tuberculosis in Accident and Emergency Departments	N/A
Completed	`NCT00763295` - Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?	N/A
Completed	`NCT01850043` - The Epidemiology of TST Change in Korea	N/A
Completed	`NCT02090374` - Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen	N/A
Completed	`NCT02073669` - Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults	N/A
Completed	`NCT02880982` - Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Completion and Acceptability of Treatment Across Primary Care and the commUnity for Latent Tuberculosis — CATAPULT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms